SCHEMBL466011

SCHEMBL466011

CCC1(C)CC(C)(C)CC(C)(N)C1

nearest known ligand 0.30

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.30
LMNA P02545 1/20 0.30
CYP2C19 P33261 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14638683 0.84
SCHEMBL658466 0.81
SCHEMBL8749785 0.80
SCHEMBL12221302 0.78
SCHEMBL466043 0.75
SCHEMBL6256959 0.75
SCHEMBL8227607 0.75
SCHEMBL339609 0.74
SCHEMBL20756316 0.74
Neramexane SCHEMBL466073 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9453017-B2 Antiviral therapies with phospholipase D inhibitors VANDERBILT UNIVERSITY (US) 2016-09-27 US claimed
US-20130123541-A1 METHOD OF PREPARING 3,3,5,5-TETRAMETHYLCYCLOHEXANONE MERZ PHARMA GMBH & CO. KGAA (DE) 2013-05-16 US claimed
US-20120130130-A1 METHOD OF PREPARING NERAMEXANE MERZ PHARMA GMBH & CO. KGAA (DE) 2012-05-24 US claimed
US-20120123166-A1 METHOD OF PREPARING 1-HYDROXY-1,3,3,5,5-PENTAMETHYLCYCLOHEXANE MERZ PHARMA GMBH & CO. KGAA (DE) 2012-05-17 US claimed
US-20120116125-A1 METHOD OF PREPARING NERAMEXANE MERZ PHARMA GMBH & CO. KGAA (DE) 2012-05-10 US claimed
EP-2448910-A1 METHOD OF PREPARING NERAMEXANE Merz Pharma GmbH & Co. KGaA (DE) 2012-05-09 EP claimed
US-20110033422-A1 TREATMENTS FOR FLAVIVIRIDAE VIRUS INFECTION SCHERING CORPORATION 2011-02-10 US claimed
EP-2277850-A1 1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists Merz Pharma GmbH & Co. KGaA (DE) 2011-01-26 EP claimed
WO-2011000538-A1 METHOD OF PREPARING NERAMEXANE MERZ PHARMA GMBH & CO. KGAA (DE) 2011-01-06 WO claimed
EP-2260839-A2 Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors Merz Pharma GmbH & Co. KGaA (DE) 2010-12-15 EP claimed
WO-2004009062-A2 NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF MICROTUBULE ASSOCIATED PROTEIN tau IQBAL KHALID (US) 2004-01-29 WO claimed
US-20040019118-A1 NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau IQBAL KHALID (US) 2004-01-29 US claimed
CN-1136187-C 1-amino-alkylcyclohexane NMDA receptor antagonists Ī�Ĺɷݹ�˾ 2004-01-28 CN claimed
CN-1461213-A 1-amino-alkylcyclohexanes as trypanocidal agents MERZ & CO GMBH & CO (DE) 2003-12-10 CN claimed
US-6602862-B1 1-Amino-alkylcyclohexanes as trypanocidal agents MERZ PHARMA GMBH & CO., KGAA (DE) 2003-08-05 US claimed
EP-1009732-B1 1-AMINO-ALKYLCYCLOHEXANE NMDA RECEPTOR ANTAGONISTS MERZ & CO GMBH & CO (DE) 2003-05-21 EP claimed
CN-1266423-A 1-amino-alkylcyclohexane NMDA receptor antagonists MERZ & CO GMBH & CO (DE) 2000-09-13 CN claimed
EP-1009732-A2 1-AMINO-ALKYLCYCLOHEXANE NMDA RECEPTOR ANTAGONISTS MERZ + CO. GmbH & Co. (DE) 2000-06-21 EP claimed
US-6034134-A 1-Amino-alkylcyclohexane NMDA receptor antagonists MERZ + CO. GMBH & CO. (DE) 2000-03-07 US claimed
WO-1999001416-A2 1-AMINO-ALKYLCYCLOHEXANE NMDA RECEPTOR ANTAGONISTS MERZ + CO. GMBH & CO. (DE) 1999-01-14 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110033422-A1 TREATMENTS FOR FLAVIVIRIDAE VIRUS INFECTION HAVCR2, EIF2AK2, HNRNPC KDM4E 4072/4885LMNA 2114/4885CYP2C19 3960/4885
US-20130123541-A1 METHOD OF PREPARING 3,3,5,5-TETRAMETHYLCYCLOHEXANONE NT5C3B, PPIP5K2, TET3 KDM4E 1547/4885LMNA 1028/4885CYP2C19 464/4885
US-20040019118-A1 NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau GRIN2A, GRIN1, MAPT KDM4E 2477/4885LMNA 3937/4885CYP2C19 4876/4885
US-20120130130-A1 METHOD OF PREPARING NERAMEXANE DHPS, TOP1, NME1 KDM4E 3578/4885LMNA 907/4885CYP2C19 1525/4885
US-20120123166-A1 METHOD OF PREPARING 1-HYDROXY-1,3,3,5,5-PENTAMETHYLCYCLOHEXANE HVCN1, HTR1D, HTR1F KDM4E 2242/4885LMNA 878/4885CYP2C19 1808/4885
US-20120116125-A1 METHOD OF PREPARING NERAMEXANE NUDT1, NT5C3B, NME1 KDM4E 3214/4885LMNA 1473/4885CYP2C19 1349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.